All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes.

By 2 weeks, 82% of ofatumumab study participants had nearly undetectable peripheral B-cell counts, and by 12 weeks, 98% of participants had undetectable B cells.[5] The difference between ofatumumab and infused MAbs is presumed to be due to the larger drug doses that can be administered intravenously compared to subcutaneously. Thus, rituximab and ofatumumab deplete B cells primarily through complement fixation, whereas ocrelizumab and ublituximab deplete B cells more through ADCC.[1] The net effect of treatment with these antibodies is rapid B-cell depletion to undetectable levels in peripheral blood that is sustained by ongoing treatment. Ocrelizumab depletes B cells in peripheral blood such that by 2 weeks post-treatment B cells are no longer detectable.[2] Rituximab also results in rapid, near-total B-cell depletion 2 weeks after treatment.[3] In a phase 2 study of ublituximab, B-cell counts were reduced by 97%, 24 hours after the first infusion, and by 4 weeks, B-cell depletion was reduced by >99% from baseline.[4] Ofatumumab reduces B cells slightly less rapidly than the other MAbs. [Extracted from the article]

Copyright of Multiple Sclerosis Journal is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)